NAD+ 1000mg Vitamin B3 derivative (30ml)

NAD+

Vitamins

Vitamin Injections

Distributed by Teleta Pharma Ltd, an MHRA Accredited, WDA Certified and GDP Compliant pharmaceutical wholesaler.
Product supplied through professional prescription channels in line with UK medicines supply regulations.

Distributed by Teleta Pharma Ltd, an MHRA Accredited, WDA Certified and GDP Compliant pharmaceutical wholesaler.
Product supplied through professional prescription channels in line with UK medicines supply regulations.

Vitamin Injections

Description

NAD+ 1000mg Vitamin B3 derivative (30ml) is a clinical-grade Nicotinamide Adenine Dinucleotide (NAD+) injectable supplement for professional use, supplied in a 30ml vial containing 1000mg of high-purity NAD+. It is designed for administration via intravenous infusion or subcutaneous injection, with flexible dosing that can be tailored by healthcare professionals to individual patient needs. NAD+ is a vitamin B3-derived coenzyme involved in cellular energy production, DNA repair, neuroprotection, metabolic regulation and healthy ageing. Endogenous NAD+ levels naturally decline with age, and supplementation may help support optimal cellular function, recovery, cognitive performance and overall vitality. This product is supplied as a cold-chain item and must be stored refrigerated between 2–8°C.

Bnefits

Provides 1000mg of high-purity NAD+ in a 30ml vial for professional use.
Supports cellular energy production (ATP synthesis) through its role as a key coenzyme.
Supports DNA repair and cellular defence mechanisms.
Supports neuroprotection and cognitive function.
Supports metabolic regulation and healthy ageing processes.
Flexible dosing allows individualisation of treatment by a healthcare professional.
Injectable formulation suitable for intravenous infusion or subcutaneous injection.
Cold-chain product supplied by an MHRA-accredited, WDA-certified, GDP-compliant pharmaceutical wholesaler.

Indications

For professional use in adults where a qualified healthcare professional has determined that NAD+ supplementation is appropriate.
To support cellular energy production and help address fatigue or reduced physical performance, as part of a clinician-supervised protocol.
To support cognitive function and neuroprotection within a broader treatment plan determined by a healthcare professional.
To support metabolic regulation and healthy ageing where NAD+ optimisation is part of the therapeutic strategy.
Use only under the direction and supervision of a suitably qualified prescriber in accordance with local regulations and guidelines.

Composition

Nicotinamide Adenine Dinucleotide (NAD+) 1000mg per 30ml vial (vitamin B3 derivative coenzyme).
Aqueous injectable solution base (exact excipient composition not specified by the distributor in publicly available information).

Formulation

Sterile injectable solution intended for intravenous infusion or subcutaneous injection.
High-purity NAD+ (vitamin B3 derivative) in solution for parenteral administration.
Professional-use-only formulation supplied via prescription channels.

Packaging

1 x 30ml vial containing a total of 1000mg NAD+.
Cold chain product; must be kept refrigerated between 2–8°C during storage and transport.
Supplied as part of Teleta Pharma’s NAD+ vitamin injection range.

Usage

For professional use only; administration should be performed by a suitably qualified healthcare professional.
Route of administration: intravenous infusion or subcutaneous injection, as determined by the prescriber.
Dosage and dosing schedule must be individualised by the healthcare professional based on the patient’s health goals, clinical status, concomitant conditions and medications.
Ensure the product has been stored within the specified temperature range (2–8°C) and that cold chain has been maintained prior to use.
Use in accordance with relevant local regulations, professional guidelines and institutional protocols for parenteral vitamin and coenzyme therapies.
Do not use if the vial appears damaged, the solution is discoloured, contains particulate matter, or if there is any doubt about cold-chain integrity.
Record batch number and administration details in the patient’s clinical notes as per local pharmacovigilance and documentation requirements.

Contraindications

Specific contraindications are not stated in the publicly available product information.
Use is not recommended without prior assessment by a qualified healthcare professional.
Healthcare professionals should consider standard contraindications to intravenous and subcutaneous therapies (e.g. known hypersensitivity to components, relevant comorbidities) and follow local clinical guidelines.

Adverse Effects

No specific adverse effects are listed in the distributor’s publicly available product information.
As with other intravenous or subcutaneous injections, potential risks may include local injection-site reactions, infusion-related reactions or hypersensitivity; clinicians should monitor patients appropriately.
Healthcare professionals should report suspected adverse reactions via appropriate pharmacovigilance channels and follow local safety reporting requirements.

Storage Conditions

Cold chain product.
Store refrigerated between 2–8°C.
Do not freeze.
Maintain cold chain during transport and handling in accordance with GDP (Good Distribution Practice) principles.
Keep out of reach of unauthorised personnel and store in accordance with institutional medicine storage policies.

Duration

Not specified by the distributor; treatment duration and frequency should be defined by the prescribing healthcare professional based on individual patient needs and response.